Results 161 to 170 of about 6,076 (222)
Some of the next articles are maybe not open access.

Related searches:

Mometasone Furoate

Drugs, 2008
Mometasone furoate (Nasonex) is a high-potency intranasal corticosteroid available for the treatment and/or prophylaxis of the nasal symptoms of seasonal allergic rhinitis (SAR) and perennial allergic rhinitis (PAR). In the EU, it is approved for use in patients aged > or =6 years and, in the US, it is approved as a treatment in patients aged > or =2 ...
Claudine M, Baldwin, Lesley J, Scott
openaire   +3 more sources

Antibacterial Activity of Mometasone Furoate

Archives of Otolaryngology–Head & Neck Surgery, 2008
To test the antibacterial properties of the topical corticoid mometasone furoate, which is used as a nasal spray.The activity of mometasone (0.01%, 0.1%, and 0.5%) in buffer solution against Staphylococcus aureus, Pseudomonas aeruginosa, Escherichia coli, Streptococcus pyogenes, and Streptococcus milleri was tested by quantitative killing assays.In ...
Andreas, Neher   +3 more
openaire   +2 more sources

Comparative clinical pharmacology of mometasone furoate, fluticasone propionate and fluticasone furoate

Pulmonary Pharmacology & Therapeutics, 2022
To investigate the pharmacokinetics and effects on the hypothalamic-pituitary-adrenal (HPA) axis of mometasone furoate (MF), fluticasone propionate (FP) and fluticasone furoate (FF).Study 1: Fourteen healthy participants received inhaled and intravenous MF (inhaled dose via Twisthaler) and FP (inhaled dose via Diskus), both given at 400 μg, using a ...
Peter T, Daley-Yates   +3 more
openaire   +2 more sources

Mometasone Furoate

Drugs, 1998
Mometasone furoate is a synthetic corticosteroid which has been evaluated for intranasal use in the treatment of adults and children with allergic rhinitis. In several large, well-controlled clinical trials, mometasone furoate 200 micrograms administered once daily as an aqueous intranasal spray was significantly more effective than placebo in ...
S V, Onrust, H M, Lamb
openaire   +2 more sources

Home - About - Disclaimer - Privacy